Sandra Costa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/858969/publications.pdf

Version: 2024-02-01

49 papers	2,962 citations	201385 27 h-index	205818 48 g-index
49 all docs	49 docs citations	49 times ranked	5022 citing authors

#	Article	IF	Citations
1	ASSOCIATION OF SERUM VASOGENIC AND PROINFLAMMATORY FACTORS WITH CLINICAL RESPONSE TO ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR FOR DIABETIC MACULAR EDEMA. Retina, 2021, 41, 345-354.	1.0	2
2	Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients. Molecular Biology Reports, 2020, 47, 877-886.	1.0	9
3	Serum proâ€inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to antiâ€•VEGF : association with intravitreal injection treatment profiles in realâ€world setting. Acta Ophthalmologica, 2020, 98, e421-e427.	0.6	3
4	Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity. Nature Communications, 2020, 11, 2282.	5.8	68
5	The Tâ€box transcription factor brachyury behaves as a tumor suppressor in gliomas. Journal of Pathology, 2020, 251, 87-99.	2.1	10
6	Genetic variants of vascular endothelial growth factor predict risk and survival of gliomas. Tumor Biology, 2018, 40, 101042831876627.	0.8	9
7	Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF. Journal of Diabetes and Its Complications, 2018, 32, 643-649.	1.2	12
8	Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis. Journal of Neuro-Oncology, 2017, 132, 27-34.	1.4	36
9	Neonatal dilated cardiomyopathy. Revista Portuguesa De Cardiologia, 2017, 36, 201-214.	0.2	18
10	MET is required for the recruitment of anti-tumoural neutrophils. Nature, 2015, 522, 349-353.	13.7	359
11	Impact of TGF-Î²1Â-509C/T and 869T/C polymorphisms on glioma risk and patient prognosis. Tumor Biology, 2015, 36, 6525-6532.	0.8	13
12	Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p. PLoS ONE, 2015, 10, e0143262.	1.1	8
13	A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget, 2015, 6, 7657-7674.	0.8	46
14	Immunoglobulin genes implicated in glioma risk. OncoImmunology, 2014, 3, e28609.	2.1	14
15	PHD2 regulates arteriogenic macrophages through TIE2 signalling. EMBO Molecular Medicine, 2013, 5, 843-857.	3.3	40
16	The Impact of Polymorphic Variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the Risk and Prognosis of Portuguese Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e72373.	1.1	26
17	Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance. Oncology Letters, 2012, 4, 647-657.	0.8	9
18	Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkinâ€™s lymphoma is not associated with prognosis. Oncology Letters, 2012, 4, 1285-1289.	0.8	5

#	Article	IF	Citations
19	Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a caseâ€“control study. Tumor Biology, 2012, 33, 1341-1348.	0.8	17
20	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature, 2011, 479, 122-126.	13.7	265
21	HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF. Cancer Cell, 2011, 19, 31-44.	7.7	628
22	Impact ofEGFRGenetic Variants on Glioma Risk and Patient Outcome. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2610-2617.	1.1	37
23	Association betweenEGF+61A/G polymorphism and gastric cancer in Caucasians. World Journal of Gastroenterology, 2011, 17, 488.	1.4	19
24	Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Research, 2009, 11, R40.	2.2	134
25	XRCC1 Arg399Gln and RAD51 5â€²UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients. Breast Cancer Research and Treatment, 2008, 109, 183-185.	1.1	20
26	Importance of TP53 codon 72 and intron 3 duplication 16bppolymorphisms in prediction of susceptibility on breast cancer. BMC Cancer, 2008, 8, 32.	1.1	98
27	TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genetics and Cytogenetics, 2008, 180, 14-19.	1.0	21
28	Opinion on moderate/low cancer genetic risk markers in medical practice including comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15. Hereditary Cancer in Clinical Practice, 2008, 6, 64.	0.6	0
29	Association between Functional EGF+61 Polymorphism and Glioma Risk. Clinical Cancer Research, 2007, 13, 2621-2626.	3.2	82
30	Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer. Cancer Letters, 2007, 246, 324-330.	3.2	15
31	Immunohistochemical expression of VEGF-A and its ligands in non-neoplastic lesions of the breast sampling-assisted by dynamic angiothermography. Oncology Reports, 2007, , .	1.2	1
32	DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Research and Treatment, 2007, 103, 209-217.	1.1	86
33	VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathology Research and Practice, 2005, 201, 93-99.	1.0	29
34	Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population. Prostate, 2005, 64, 246-252.	1.2	34
35	DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil. Genetics and Molecular Research, 2005, 4, 771-82.	0.3	50
36	TP73 alterations in cervical carcinoma. Cancer Genetics and Cytogenetics, 2004, 150, 116-121.	1.0	26

#	Article	IF	Citations
37	Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. Journal of Pathology, 2004, 202, 330-335.	2.1	73
38	Metabolic susceptibility genes and prostate cancer risk in a southern European population: The role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate, 2004, 58, 414-420.	1.2	84
39	Overexpressing leptin genetic polymorphism (?2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate, 2004, 59, 268-274.	1.2	84
40	HER2 polymorphism and breast cancer risk in Portugal. European Journal of Cancer Prevention, 2004, 13, 177-181.	0.6	38
41	Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S -transferase genetic polymorphisms as predictive biomarkers of disease outcome. International Journal of Clinical Oncology, 2003, 8, 156-161.	1.0	68
42	Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genetics and Cytogenetics, 2003, 141, 91-96.	1.0	39
43	Endothelial nitric oxide synthase gene polymorphisms and the shedding of circulating tumour cells in the blood of prostate cancer patients. Cancer Letters, 2003, 189, 85-90.	3.2	31
44	Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. European Journal of Cancer Prevention, 2003, 12, 205-211.	0.6	33
45	Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. European Journal of Cancer Prevention, 2002, 11, 343-350.	0.6	74
46	A slow acetylator genotype associated with an increased risk of advanced cervical cancer. Journal of Cancer Research and Clinical Oncology, 2002, 128, 678-682.	1.2	21
47	The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. Journal of Human Genetics, 2002, 47, 413-418.	1.1	69
48	Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate, 2002, 53, 88-94.	1.2	53
49	Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clinical Cancer Research, 2002, 8, 3433-7.	3.2	46